BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21119606)

  • 1. Connective tissue diseases: Treatment of digital ulcers in systemic sclerosis.
    Lambova S; Müller-Ladner U
    Nat Rev Rheumatol; 2011 Jan; 7(1):5-6. PubMed ID: 21119606
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study.
    Hamaguchi Y; Sumida T; Kawaguchi Y; Ihn H; Tanaka S; Asano Y; Motegi SI; Kuwana M; Endo H; Takehara K
    J Dermatol; 2017 Jan; 44(1):13-17. PubMed ID: 27374274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New hope for systemic sclerosis patients with digital ulcers.
    Varga J
    Curr Rheumatol Rep; 2005 Apr; 7(2):127-8. PubMed ID: 15760591
    [No Abstract]   [Full Text] [Related]  

  • 4. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
    Matucci-Cerinic M; Denton CP; Furst DE; Mayes MD; Hsu VM; Carpentier P; Wigley FM; Black CM; Fessler BJ; Merkel PA; Pope JE; Sweiss NJ; Doyle MK; Hellmich B; Medsger TA; Morganti A; Kramer F; Korn JH; Seibold JR
    Ann Rheum Dis; 2011 Jan; 70(1):32-8. PubMed ID: 20805294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis.
    Dhillon S
    Drugs; 2009 Oct; 69(14):2005-24. PubMed ID: 19747014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists.
    Ngcozana T; Ong V; Denton CP
    BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24682137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
    Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
    Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosentan for digital ulcers prevention does not worsen cardiopulmonary exercise test parameters in SSc patients with interstitial lung disease.
    Romaniello A; Gigante A; Di Paolo M; Tallerini G; Barbano B; Amoroso D; Palange P; Rosato E
    Int J Cardiol; 2016 Nov; 223():113-115. PubMed ID: 27537734
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.
    Humbert M; Cabane J
    Rheumatology (Oxford); 2003 Jan; 42(1):191-3. PubMed ID: 12509640
    [No Abstract]   [Full Text] [Related]  

  • 10. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
    Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
    Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
    [No Abstract]   [Full Text] [Related]  

  • 11. Bosentan in systemic sclerosis.
    Heresi GA; Minai OA
    Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.
    Tsifetaki N; Botzoris V; Alamanos Y; Argyriou E; Zioga A; Drosos AA
    J Rheumatol; 2009 Jul; 36(7):1550-2. PubMed ID: 19567637
    [No Abstract]   [Full Text] [Related]  

  • 13. Resolution of severe digital ulceration during a course of Bosentan therapy.
    Snyder MJ; Jacobs MR; Grau RG; Wilkes DS; Knox KS
    Ann Intern Med; 2005 May; 142(9):802-3. PubMed ID: 15867420
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of digital ulcers in systemic sclerosis: Case series study of thirteen patients and discussion on outcome.
    Abuowda Y; Almeida RS; Oliveira AA; Pego P; Santos C; Matos-Costa J
    Rev Assoc Med Bras (1992); 2017 May; 63(5):422-426. PubMed ID: 28724039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Digital ulcers in systemic sclerosis: use of endotheline antagonists].
    Mota J; Castellano A; Santiago F; Carvalho P; Madeira AS; Pereira De Moura JM; Nascimento Costa JM
    Acta Med Port; 2011; 24(5):837-42. PubMed ID: 22525638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.
    Tillon J; Hervé F; Chevallier D; Muir JF; Levesque H; Marie I
    Br J Dermatol; 2006 May; 154(5):1000-2. PubMed ID: 16634913
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.
    Khanna D; Denton CP; Merkel PA; Krieg T; Le Brun FO; Marr A; Papadakis K; Pope J; Matucci-Cerinic M; Furst DE; ;
    JAMA; 2016 May; 315(18):1975-88. PubMed ID: 27163986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].
    Riemekasten G; Beissert S; Distler JH; Kreuter A; Müller-Ladner U
    Z Rheumatol; 2017 Apr; 76(3):228-237. PubMed ID: 27535277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
    Botzoris V; Drosos AA
    Joint Bone Spine; 2011 Jul; 78(4):341-6. PubMed ID: 21183379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)].
    Riccardi MT; Chialà A; Lannone F; Grattagliano V; Covelli M; Lapadula G
    Reumatismo; 2007; 59(2):135-9. PubMed ID: 17603693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.